Novocure Ltd. Stock

$17.88

0.45% yesterday

Nasdaq, Jul 01, 10:15 pm CET

ISIN

JE00BYSS4X48

Symbol

NVCR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Novocure Ltd. Stock price

$17.88

-41.73 70.01% 5Y

Nasdaq, Closing price Tue, Jul 01 2025

+0.08 0.45%

ISIN

JE00BYSS4X48

Symbol

NVCR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$2.0b

Enterprise Value

$1.7b

Net debt

positive

Cash

$929.1m

Shares outstanding

111.5m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

3.21 | 3.12

EV/Sales

2.77 | 2.69

EV/FCF

negative

P/B

5.51

Financial Health

Equity Ratio

29.03%

Return on Equity

-46.82%

ROCE

-32.56%

ROIC

-153.79%

Debt/Equity

1.81

Financials (TTM | estimate)

Revenue

$621.7m | $638.9m

EBITDA

$-152.8m | $-66.9m

EBIT

$-164.6m

Net Income

$-164.2m | $-187.5m

Free Cash Flow

$-72.1m

Growth (TTM | estimate)

Revenue

18.27% | 5.56%

EBITDA

23.99% | 57.47%

EBIT

22.41%

Net Income

14.81% | -11.16%

Free Cash Flow

40.37%

Margin (TTM | estimate)

Gross

77.16%

EBITDA

-24.58% | -10.47%

EBIT

-26.47%

Net

-26.41% | -29.34%

Free Cash Flow

-11.60%

EPS

$-1.48

FCF per Share

$-0.65

Short interest

7.02%

Employees

1.49k

Rev per Employee

$410.00k

As a Free StocksGuide user, you can view scores for all 6,952 stocks worldwide.

Get Started for Free Today

Novocure Ltd. Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Novocure Ltd. forecast:

10x Buy

77%

3x Hold

23%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Novocure Ltd. forecast:

Buy

77%

Hold

23%

Analyst Estimates with Stock Price Targets

Financial data from Novocure Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	622 622	18% 18% 100%
- Direct Costs	142 142	7% 7% 23%
Gross Profit	480 480	22% 22% 77%
- Selling and Administrative Expenses	432 432	11% 11% 70%
- Research and Development Expense	212 212	1% 1% 34%
EBITDA	-153 -153	24% 24% -25%
- Depreciation and Amortization	12 12	6% 6% 2%
EBIT (Operating Income) EBIT	-165 -165	22% 22% -26%
Net Profit	-164 -164	15% 15% -26%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Novocure Ltd. Stock News

Neutral

Business Wire

●

one day ago

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic cancer. These data from PANOVA-3 were accepted as a late-breaking abstract for oral presentation at the European Society for Medical Onco...

Neutral

Business Wire

●

2 days ago

Novocure to Report Second Quarter 2025 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 24, to discuss the company's financial results for the three- and six-month periods that ended June 30, 2025. To access the conference cal...

Neutral

Business Wire

●

about one month ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in ...

More Novocure Ltd. News

Company Profile

NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Head office	Jersey
CEO	Ms. Cordova
Employees	1,488
Founded	2000
Website	www.novocure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now